RESULTS
IgA antibody response to EBV VCA in IM. Development of IgA antibodies to VCA during IM was documented in 14 patients (74%). These antibodies developed very rapidly, and the titers declined soon after reaching their peak levels ( Fig. 1 ). There was a significant (P < 0.001) fall in the geometric mean titer comparing the convalescent-phase titers (3.5 to 9 weeks) with the preceding acute-phase titers. Only one patient had IgA antibodies after 10 weeks, and after 24 weeks all were negative.
Time course of other antibodies in IM: IgG and IgM antibodies to VCA, anti-EA, anti-EBNA, and heterophile antibodies. As shown in Fig. 2 , IgG antibodies to VCA appeared soon after the onset of illness, and frequently the titer was maximal in the first serum sample. There was a slight rise in geometric titer at 1.5 to 3 weeks, but the titers then remained stable during the entire observation period. IgM antibodies to VCA likewise developed promptly, and both IgG and IgM VCA antibodies occurred in all patients studied, but the latter rapidly declined, as did the IgA antibodies. After 10 weeks only two patients had IgM VCA antibodies, and after 20 weeks all were IgM antibody negative.
Seventeen patients (89%) developed antibodies to EA, and these remained elevated, unlike the IgM and IgA VCA antibodies. In all patients who developed EA antibodies, the antibody persisted to the end of the study period.
All patients except one developed heterophile antibodies, which appeared early, peaked in the 1.5-to 3-week interval, and then rapidly declined, similar to the IgA and IgM VCA antibod- ies. Of these three antibodies, which correlated closely in their kinetics, the IgM antibody tended to persist slightly longer after the peak response. No patients had heterophile antibody after 10 weeks of illness.
IM patients without IgA antibody to VCA. The IM patients without IgA antibody to VCA included five patients in whom no IgA antibodies to VCA were detected during IM. In this group of patients, there were some serological and clinical peculiarities. The IgM antibody response to VCA was normal in these patients, but the IgG antibodies to VCA seemed to develop slightly slower than in the other patients. One of these patients had a seroconversion in VCA IgG antibodies during his illness, which is rare in IM (most patients are seropositive when first seen). Another had a significant rise in VCA IgG titer from 20 to 160, whereas no such rises in VCA IgG titers were seen in the IgA antibodypositive patients. The clinical course of these two patients was also exceptional. They both had extremely swollen lymph nodes, their overall illness was very severe initially, and they were given a short course of steroids between 15 and 20 and between 18 and 22 days after onset, respectively. The first serum sample with the absent or low IgG antibody titers was taken from both patients before the steroids were started. Both of these patients had a prolonged course of illness with symptoms of fever, adenopathy, and pharyngitis up to week 9 after onset, which is unusual in this illness (12) , and they also felt extreme fatigue for several weeks after recovery. The three other patients had a normal clinical course of IM. However, two of these were EA antibody negative, the only such patients in this population. The third had heterophile-negative IM, also the only such case in this population. Even the two heterophile-positive, EA antibodynegative, IgA antibody-negative pati'ents had a very low and short heterophile antibody response, with a maximum titer of 1:56. Antibodies to EBNA also seemed to develop slower in the IgA antibody-negative patients. Three of these patients were EBNA antibody negative 6.5, 9, and 31 weeks postonset, when most patients were already anti-EBNA positive.
The two patients with severe illness and a slow EBV antibody response had, however, a normal cellular response to phytohemagglutinin and EBV antigens (12) . One of these had a delayed response, however, considered likely to be due to the steroids (18 (2) reported that 75% of patients with clinical influenza developed IgA serum antibodies which disappeared completely by 10 weeks. Conversely, IgA antibodies to rubella virus have been reported to persist in some cases for several months up to 3 years after the onset of illness (1, 10). Schmitz and Haas (17) stated that IgA antibodies to cytomegalovirus developed simultaneously with the IgM antibodies in a recent infection. Both classes of antibodies were detectable in the acute phase. The IgA antibodies to cytomegalovirus seemed to persist somewhat longer than the IgM-class antibodies. Thus, there appear to be differences in the persistence of IgA antibodies in different viral infections.
The IgA antibody-negative IM patients had some exceptional clinical and serological features. Two of these patients had delayed heterophile, IgG, and IgM antibody responses, and one of these also showed a delay in production of antibody to EA. These two patients also had an unusually severe and prolonged course of illness. It is unlikely that the steroids were responsible for the aberrant antibody kinetics, since the slow IgG response was documented before the steroids were given, and the steroids were given after the peak IgA responses were seen in the remaining patients. The three other IgA antibody-negative patients had a usual: course of illness, but they had absent or low heterophile and anti-EA antibody responses and a delay in appearance of EBNA antibody. The patients with deficient IgA VCA responses were not studied with respect to IgA immunoglobulin deficiency.
It will be of interest in future studies to see whether all heterophile-negative and EA antibody-negative cases of IM (serologically proven by other tests) are also negative for IgA antibody to VCA. A lack of an IgA response in IM could be a marker for a relative deficiency in the EBV antibody response. This might in some cases be associated with a more severe illness. Since the target cell for the EBV infection is a B lymphocyte, which is essential in humoral antibody production, this association may signal a subgroup with a more severe infection. Absence of this antibody could be of prognostic value with regard to the duration of illness or of use in selecting patients for the study of drugs (e.g., steroids) for severe forms of the disease. Information on the status of IgA secretory antibody to EBV would also be of interest in IM.
